Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Persistence of stigma toward people living with HIV has puzzled scientists looking at the numerous destigmatization campaigns ...

The U.S. government's foreign aid freeze has upended the supply chain for medical products crucial for fighting diseases ...

Two-year-old Evans was brought to the Nyumbani Children’s Home in Nairobi, Kenya a year ago, suffering from HIV and ...

Transmission electron micrograph of HIV-1 virus particles (teal) exiting an infected immune cell after replicating inside the cell. Inset: Interior view a HIV-1 virus showing the capsid (yellow) that ...

The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...

HIV is spread by bodily fluids such as blood, breast milk or semen. It gradually weakens the body's immune system and makes ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market ...

Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

a group that campaigns for access to AIDS treatment. “For PEPFAR, which is the bulk of the global AIDS response, it means stopping service delivery, many people will die and become HIV positive.” ...

Future Virology. 2012;7(12):1145-1147. Physicians caring for INR HIV-infected subjects struggle between two opposite options: leave ARV therapy as it is or start an experimental therapy in order ...

A groundbreaking medical advancement could reshape the future of HIV prevention. In a landmark clinical trial, a twice-yearly injection of lenacapavir demonstrated an astonishing 96% effectiveness ...